NTRB Stock Analysis: Buy, Sell, or Hold?
NTRB - Nutriband Inc. Common Stock
$2.96
-0.13 (-4.21%)
▼
5d:
-3.27%
30d:
-16.15%
90d:
-23.12%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: May 29, 2026
0d
Get Alerted When NTRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NTRB shows positive signals but monitor for confirmation. Market pricing in 8.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NTRB shows positive signals but monitor for confirmation. Market pricing in 8.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.49
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.41
13.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NTRB is currently trading at $2.96, which is considered oversold relative to its 30-day fair value range of $3.01 to $3.43. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.0) compared to its historical average (2.7). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NTRB is in a strong downtrend. The price is currently testing key support at $3.21. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+406.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NTRB is in a strong downtrend. The price is currently testing key support at $3.21. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+406.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.01 -
$3.43
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 406.8% below Wall St target ($15.00)
Trading Range Analysis
30-Day Trading Range
$3.01 -
$3.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.21
Resistance Level
$3.69
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.04
Wall Street Target
$15.00
(+406.8%)
Revenue Growth (YoY)
-35.1%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
2.0 vs 2.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$2.70
(-9%)
2-Year Target
$2.46
(-17%)
3-Year Target
$2.25
(-24%)
3-Yr Target (if PE normalizes)
(PE: 2→3)
$2.97
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.0 to 2.7
Stabilization Target:
$3.92
(+32.3%)
PE Expansion Potential:
+32.3%
Share & Embed Analysis
Last updated: July 13, 2026 4:04 AM ET
Data refreshes hourly during market hours. Next update: 5:04 AM
Data refreshes hourly during market hours. Next update: 5:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 64 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 63 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 62 BUY |
